Daily Newsletter

25 October 2023

Daily Newsletter

25 October 2023

AstraZeneca and Daiichi Sankyo’s breast cancer drug cuts disease progression by 37%

Datopotamab deruxtecan reduced the risk of disease progression by 37% in interim data from Phase III trial presented at the ESMO 2023 congress.

Jenna Philpott October 24 2023

Daiichi Sankyo and AstraZeneca have reported positive interim data for datapotamab deruxtecan (Dato-DXd) to treat inoperable or metastatic hormone receptor (HR) positive, HER2 negative breast cancer, previously treated with endocrine-based therapy and systemic therapy.  

The companies presented data from the TROPION-Breast01 (NCT05104866) trial in a Presidential Symposium at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid on 23 October.

Dato-DXd reduced the risk of disease progression or death by 37% compared to chemotherapy, but the results did not reach statistical significance at the time of cut-off.  

The global, randomised, multicentre, open-label Phase III trial assessed the safety and efficacy of Dato-DXd, a specifically engineered TROP2-directed DXd antibody-drug conjugate (ADC). The dual primary endpoints are progression-free survival (PFS) as assessed by the blinded independent central review (BICR) and overall survival (OS). The study enrolled more than 700 patients globally.  

AstraZeneca oncology R&D executive vice-president Susan Galbraith said: “With these TROPION-Breast01 results, datopotamab deruxtecan has the potential to meaningfully improve treatment expectations for patients with HR-positive, HER2-low or negative metastatic breast cancer.

“We look forward to continuing discussions with regulatory authorities with the goal of bringing this TROP2-directed antibody-drug conjugate to eligible patients as soon as possible.” 

Dato-DXd is currently in twelve clinical trials as part of the TROPION development programme, evaluating the drug across multiple tumours, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and hormone receptor-positive, HER2-low or negative breast cancer. 

Positive data from the TROPION-Lung01 was reported in July for Dato-DXd to treat NSCLC, which showed a statistically significant improvement in PFS compared to the standard treatment, docetaxel.  

According to GlobalData, Dato-DXd’s sales forecast is estimated to exceed $2.5bn by 2029. GlobalData predicts that AstraZeneca/Daiichi Sankyo’s datopotamab deruxtecan will lead the market. GlobalData is the parent company of Clinical Trials Arena. 

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close